VRG Technologies, Inc.

 

 Home Up Products Patents Investing Press Releases Contacts

  Immune Disease
 
Home
Up
 
 

 

Vector Research - Global Technologies.


WORLDWIDE MARKET FOR PRESCRIPTION DRUGS TO TREAT SELECTED IMMUNE DISEASES TO REACH $44 BILLION IN 2003

Immune diseases are found in a substantial proportion of the
population. These diseases are often chronic, debilitating and life-threatening and many currently have no cure. The majority of immune diseases are rare in occurrence and not well known. However, drugs to treat the leading immune  diseases -- excluding acquired immune deficiency syndrome (AIDS) and cancer--represented in 1998 approximately 10% of the

approximately $250 billion world prescription drug market. This market report on advances in the treatment of immune diseases provides a comprehensive assessment of the current state of technical advances as well as the commercial and market potential of products and programs in development at various companies and institutions.

According to a soon-to-be-released BUSINESS COMMUNICATIONS CO., INC. study RC-141R
Immune Diseases: Advances in Diagnosis and Treatment Products, the world prescription pharmaceuticals market was estimated at approximately $280 billion in 1998 and is projected to
approach $450 billion by 2003. Drugs to treat leading immune  diseases (excluding acquired immune deficiency syndrome -- AIDS--and cancer) represented approximately 10% of the world
prescription drug market in 1998. This market will rise to $44 billion by 2003, growing at an average annual growth rate (AAGR) of 8.8 % from 1998 to 2003. 

Several categories within this market will witness double-digit AAGRs as more effective (and more expensive) products are introduced for the first time to replace older agents or products that treat a
particular disease. The market for the treatment of asthma comprised nearly 30% of the $29 billion prescription drug market in 1998. This is expected to grow at an AAG R of 10.1% from 1998 to 2003 to reach $14 billion in 2003.

Cyclo-oxygenase (COX)-2 inhibitors, the first of which received U.S. market approval in January 1999, will give a substantial boost to the rheumatoid arthritis market by providing excellent control of inflammation and pain without the side effects associated with older anti-inflammatories. This market was estimated at $6.4 billion in 1998 and is expected to reach $8.8 billion in 2003, growing at an AAGR of 6.5% during the five-year period. 

In the treatment market for Type I diabetes mellitus, insulin analogs are being introduced that offer greater efficacy and are priced substantially higher than older products. This market is growing at
an AAGR of 10.3% from 1998 to 2003.

Products that specifically treat multiple sclerosis began to enter the market in 1993, and this sector will see an average annual growth exceeding 19% because of continued introduction and use of these
innovative and effective treatments. Being the fastest growing market, it will rise from an estimated $1.3 billion in 1998 to $3.2 billion in 2003.
 

WORLDWIDE MARKET FOR PRESCRIPTION DRUGS TO TREAT SELECTED IMMUNE DISEASES, 1998-2003
($ Millions)
Disease 1998 2003 AAGR%
1998-2003
Rheumatoid arthritis (disease modifying 
antirheumatic drug)
6,420.0 8,800.0 6.5
Insulin-dependent diabetes mellitus 
(insulin)
1,550.0 2,530.0 10.3
System lupus erthematosus 1,980.0 2,190.0 2.1
Multiple sclerosis 1,320.0 3,200.0 19.4
Scleroderma 910.0 980.0 1.5
Mysathenia gravis 109.0 116.0 1.3
Graft versus host disease 11.5 21.9 13.8
Organ transplant rejection 2,550.0 3,720.0 7.8
Allergic 5,450.0 8,650.0 9.7
Asthma 8,820.0 14,250.0 10.1
Total 29,120.5 44,457.9 8.8

RC-141R Immune Diseases: Advances in Diagnosis and Treatment Products

Published: July 1999

Data and analysis provided courtesy of BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT 06855,  Telephone: (203) 853-4266; ext. 309,  Email: publisher@bccresearch.com
 

Back Home Up Next 

     

VRG Technologies, Inc.

Last Modified : 12/10/01 07:09 PM

Copyright 2001